A Future-Oriented Loan For Inura

Congratulations to our portfolio company Inura for being selected for the loan “100 fürs Baselbiet” from BLKB. Inura will receive a total of 500,000 CHF!

 
“100 fürs Baselbiet” is an initiative organized by BLKB, the University of Applied Sciences Northwestern Switzerland FHNW, and the Baselland Economic Development Agency. This future-oriented program facilitates access to financial resources as well as advisory services for innovative SMEs and start-ups related to the Basel area.
 
The “100 fürs Baselbiet” purpose is based on strong collaborations between industry, science, and government. The goal is to help SMEs and start-ups to expand. Besides, this initiative intends to enhance the attractiveness and innovative capabilities, create jobs, and add economic value to the region. Interested companies have gone through a two-stage selection process. First, you submit your business idea with the associated financial plan. Afterward, if there is positive feedback, an independent advisory board assesses the companies’ applications pre-selected in so-called pitches. Subsequently, the Advisory Board decides which ideas and companies will receive support. 
 
The selected companies receive financing in the form of loans from BLKB. Obtaining this loan indicates the confidence that the Advisory Board has in the project and the team. The criteria are, among other things, the innovative strength and sustainability of the ideas presented and the quality of the entrepreneurial team. At HEMEX, we believe as well on Inura’s project and its team. Therefore, we are thrilled to see them acomplishing this achievement.
 
Inura Medical AG logoInura Medical is developing an innovative urethral suppository for women with Overactive Bladder Syndrome (OAB). This highly prevalent and disabling health disorder has a significant impact on 20% of the female population’s quality of life. For instance, sleep deprivation, fatigue, nocturia, or memory lapses. Unfortunately, around 70-90% of the patients discontinue the available treatments because of their side effects. Inura Medical’s new, patented design suppository facilitates the effective penetration of drugs through the urethral mucosal lining. This new route of administration has greater therapeutic efficacy, and there are fewer side effects. Moreover, Inura Medical’s technology will reduce healthcare costs related to the treatment of OAB. Thanks to its partnership with HEMEX, Inura can complete an entire development program until Phase 3 in which the effects of the oral and urethral administration of the drug will be compared.
 
Hemex has a strong track record in women’s health and we immediately saw the potential of Inura’s urethral suppository platform. If you would like to know more about Inura, check their website HERE.

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

Ready To Battle?

Innosuisse will select the top 15 Swiss Startups with the most sustainable solution that positively impact the climate, society, and the greater good for their Digital Day 2020

 

The fourth edition of the nationwide Swiss Digital Days with activities in locations across Switzerland will have place from the 1st– 3rd of November. As a start-up, you will have the opportunity to enhance your dialogue with the swiss public, politicians, science, and civil society. Apply for the Start-up Battle and let’s experience digital together!

 

 

How does it work?

Out of all applications, digitalswitzerland and Startup INVEST selects 15 Start-ups. These 15 Start-ups are asked for a video (max. 3min) where they pitch their impact.

The video will be shared on the digital day website and the public will be allowed to vote for the Public award.

Afterwards, the Jury will select the 5 finalists. These 5 finalists will pitch live in front of a jury at SRF Studios. Finally, the Jury will award a prize to the 3 most innovative start-ups that generate a sustainable impact.

 

What’s in it for you?

5k in cash, for the winner, and more prices to follow.

 

Important! Start-up selection criteria

-Sustainable impact on climate, society, and the greater good
-Market Potential (problem/solution fit)
-Business Model
-Team
-Innovation (IP, Magic Sauce)

 

If you are looking for funding and visibility don’t miss this opportunity. Complete and submit the form below BEFORE 30.09.2020 including the upload of your video pitch and slides. Do you need help with your Pitch Deck and Video? We can help you, contact us here: yaozi.moreno@hemex.ch

To apply directly HERE.

 

About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

Hemex Organizes Thriving Online Pitch Event

Magnes, denovoMATRIX, Bionomous, Sleepiz, and Sedimentum pitched their ventures at the HEMEX incubator to an online group of renowned international investors.

 

HEMEX has been organizing since June online Pitch Events to ensure safety for all participants. This time, the focus was directed to start-ups that are currently developing solutions to help transform health care with their breakthrough innovations. At Hemex our objective is to organize Pitch Events where selected start-ups get the opportunity to pitch in front of potential investors, and investors get the opportunity to ask them questions. Therefore facilitating the contact to speed up prosperous collaborations.

As a special guest, David C.Sutter, Program Manager of 100 fürs Baselbiet of BLKB, joined us today at our headquarters in Liestal, “It was a very interesting chance to get to know different companies, to have a first impression about their business models, and learn about their teams”, David tells to Hemex. “This kind of events are a great possibility for start-ups and investors to bring them together and have a first contact”. 1004BB promotes access to financial resources and coaching. Addressed are start-ups and small & medium enterprises (SMEs) that are related in the greater Baselland Area, either being incorporated in the region or that are expected to bring added value to the greater region.

 

Today’s event kicked off with the start-up Magnes AG. Cofounders Dr. Olgac Ergeneman and Dr. George Chatzipirpiridis, CEO and COO at Magnes respectively, presented their disruptive real-life-monitoring solution to analyze walk patterns of patients with neurological disorders. Magnes has developed a technology that, using smart sensors embedded in sneaker-like shoes, data is collected from patients during their daily activities. Their AI processes data to generate automatic reports and provide the patient with direct feedback preventing situations like freezing of gait. “We have tested our product on patients and we proved that it’s working. We are excited to see the positive reactions from patients. Helping them to improve their lifes it’s a completely different level of happiness. Now we need funding to upscale it and reach a bigger number of patients” explains George to Hemex. “Is very motivating to be able to make a change in patients’ lifes, and it’s not just about the business or the funding, seeing that you can really help someone is the big motivation” adds Olgac. Magnes’ technology can change the way clinical trials are performed today and improve efficacy by enabling data-driven therapy through tailored medication dosage.

 

The second start-up pitching at our event was denovoMATRIX. Dr. Dejan HušmanCEO & Cofounder of denovoMATRIX, presented their innovative idea. denovoMATRIX GmbH enables cell-based therapies’ acceleration through its proprietary biomaterial platform, which addresses bottlenecks in cell manufacturing. They are redefining cell culture in life science and offer modular, biomimetic coatings for cell culture plastic ware that can be tailored to recreate a large variety of extracellular matrices (ECM) for any adherent cell culture. “We believe that the significance of cell-based therapies will grow in the future, therefore manufacturing these therapies is the absolute key to successful implementation,” explains Dejan to Hemex “this is the first Pitch Event that I have taken part where there is enough time for the start-ups to pitch in a more relaxed environment. You have time to be asked questions about your project and go into more specifics with investors“. The biomaterials space is an overlooked niche, and their enabling technology will prove invaluable to key cell therapy players, making them an attractive investment.

 

 

The third start-up pitching was Bionomous. Cofounders Frank Bonnet and Ana Hernando Ariza, CEO and CMO of Bionomous respectively, presented their innovative solution. Bionomous is developing and commercializing a cost-effective robotic device that automatically carries out the screening, sorting, and dispensing of miniature biological entities, such as the zebrafish embryos, a model growing in popularity in toxicology, genetics, and cancer research. “We want to automatize the process that are using the zebrafish model, and this will not only help accelerate research but also reduce animal experimentation” tells Frank to Hemex. “The zebrafish is indeed an alternative model to reduce animal experimentation, as research can be made using the eggs and embryos, which are not considered as animals due to their very early age.” Ana also adds “With automation you also standardize the whole process. You can save a lot of mistakes and misunderstandings done in the lab and in the end you save time and money”. Their patented technology offers thus a portable and affordable solution for laboratories working intensively with the zebrafish.

 

The forth start-up pitching at our event was Sleepiz. Max Sieghold, CFO and Cofounder of Sleepiz, presented their innovative idea. Sleepiz is aiming to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable solution with a device that is simply placed on the bedside table. “We are adressing a huge market, because we are in a time point where digital health solutions for monitoring patients are really required. There is a strong need because such a huge population is affected, but we don’t have any solutions that are viable” explains Max to Hemex after his presentation. “A lot of healthcare providers have realized that from a patient side there is a need to be monitored at home. We really see the market is ready, and the market wants a solution like ours”. By using wireless millimeter wave technology, sensor fusion, and artificial intelligence, Sleepiz will not only diagnose sleep disorders but also perform long-term monitoring.Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.

 

Sandro Cilurzo, CEO of Sedimentum, presented their startup which developed the first contactless solution for fall and emergency detection in healthcare, without compromising privacy. Sedimentum‘s technological protection solution ensures the physical safety of unattended people, in a complete automated and contactless manner with a strong focus on human data privacy. “We are deeply convinced that our solution will make the lives of thousands of people safer and more autonomous in the future. With our unique technology and our ambitious team, we want to disrupt the healthcare market and make living safe.” explains Sandro to Hemex. “This great pitching event gave us the opportunity to present our vision and mission to potential investors”. Sedimentum supports and relieves the burden on nursing staff, who are informed in real-time about falls and health threatening events of their patients.

 

Many thanks to Olgac, George, Dejan, Frank, Ana, Max and Sandro for introducing us to their unique ideas and solutions. We wish you good luck with your projects!

Are you interested in becoming an early-stage investor in one of these promising start-ups? Would you like to receive a personalized invitation to one of our next sessions?

Or are you interested in learning about how to create a great pitch deck that excites potential investors about your idea?

Then you are in the right place! Contact our start-up coach Franziska Stemmler for more information.

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX

Schools with a clear mission

Community commitment should be something essential in every company that wants to make a difference in society. Here’s our suggestion to how you can help your community in Liestal

 

Hemex supports educational programs with a long-term positive impact. The SOL School for Open Learning emerged from the Freie Volksschule Basel (FVB). It was founded in 1982, and since 2000 is located in Liestal. With twenty years of experience, SOL’s basic attitude is the loving respect for life processes. When children and young people experience this basic attitude and adopt it for themselves, they acquire something necessary for the current times we live in: sustainability.

Sustainability as the process of maintaining a balance between the environment, the economy, and the social domain. Therefore, in SOL, not just the children and the young people, but also adults learn from each other and develop their vital forces to be part of a comprehensive whole. The aim is to contribute to a peaceful, solidary, and individual respecting society by promoting a sense of responsibility for the community and the ability to criticism and tolerance.

 

 

This unique school defines, assesses, and appreciates the performance of each student individually. In doing so, it takes into account the whole spectrum of human beings. Different forms of expression are considered, and both intellectual and artistic practical activities are reinforced.

If you would like to know more about SOL. The upcoming Info-Tag will be next Saturday 19th September, from 10 am – 15 pm at HANRO Areal, Liestal. For more information visit their website HERE.

 

 About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

BioReperia gains international recognition!

BioReperia has recently joined an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.

 

We are delighted to announce that our portfolio company BioReperia has taken part in an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.

RISE program connects organizations from the academic and non-academic sectors (in particular SMEs). By linking research and personnel, and sharing expertise and ideas between the innovation research field to the market field, RISE facilitates international and multisectoral cooperation. The scheme promotes a shared research and innovation culture that embraces and recognizes creativity and entrepreneurship.

This grant will help BioReperia to progress and advance their technology (zebrafish ZTX-platforms) towards IVD-precision medicine and drug discovery. The program offers assistance thought collaborative research and the development of innovation for the project. The objective is to share knowledge via international and intersectoral mobility, based on research and innovation staff allocation with an in-built return mechanism.

BioReperia’s innovative technology will shed light on immune-oncology, specifically how dysregulation in cysteine leukotriene signaling contributes to cancer development.

 

About BioReperia

BioReperia AB is a privately-owned contract research organization (CRO) founded in September 2015 based on technology developed at Linköping University in Sweden. Their technology is used to accelerate drug discovery and individual test treatments on specific patients in clinical trials. They are active as a CRO in the European market for drug discovery in academic institutions and pharmaceutical companies. BioReperia AG was incorporated at HEMEX’s incubator on december 2019 to focus on the development of IVD to fight against different types of cancers. More info at BioReperia.

 

 About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

Who are the Top 100 Swiss Start-ups in 2020?

The Top 100 Swiss Start-up celebrated a very special edition yesterday. Besides being their 10th anniversary edition, for the first time, the award show was live-streamed for safety reasons, and ran perfectly smoothly!

 

At Hemex, we are very proud of our five portfolio start-ups that have made it onto the Top 100 Swiss Start-up. For a Start-up to get onto this list is a big honour because they are selected by a panel of 100 leading investors and experts. Keep an eye on them this year because they are going to be in the spotlight of innovation! 

Firstly, we would like to congratulate ASPIVIX and Scailyte for being in the top 100!

Aspivix is developing the next-generation surgical instrument for gentle and modern gynaecological procedures. Aspivix’s device is a gentle vacuum suction-pad applied to the cervix to steady it during gynaecological procedures. Pain is minimized, there is no bleeding, the risk of cross-contamination is eliminated, and the whole experience is less traumatic.

 

Scailyte logo

Scailyte is a data-driven biomarker discovery company that detects complex disease patterns from single-cell data at the onset of disease. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. 

 

Secondly, we would like to congratulate Annaida Technologies for being in the top 50! Annaida was also second in the Top 3 best Newcomers for the Top 100 Start-up’s 2020.

Annaida Technologies logo

Annaida Technologies is the first high-tech company start-up bringing magnetic resonance to embryo scale. Annaida is an EPFL spin-off that is harnessing a technology that is delicate enough to use on a human embryo. The start-up’s device performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. 

 

Thirdly, huge congratulations to our portfolio company Resistell AG for being in the top 10! Resistell was also in the top 3 best Biotech start-ups.

Resistell logo

Resistell is a EPFL spin-off that has been able to successfully achieve reliable antibiotic susceptibility results up to 100 times faster than conventional, culture-based methods. Resistell’s test is based on the measurement of living bacteria vibrations from the sample by using nanosensors. This reduces the time-to-result from several hours or days to less than two hours. Patients can be treated with optimal medication from day one. 

 

TOP 100 Swiss Start-ups ranking brings the best investors together with the best start-ups. It’s the most prestigious start-up award in Switzerland. Being among the TOP 10 is a huge recognition and was definitely unexpected, especially given that we were incorporated only two years ago. For Resistell it’s a huge motivation to work even harder now to climb up the list next year!                                                                                                   – Danuta Cichocka, CEO of Resistell. 

 

Finally, a special mention to Sleepiz, who won the public vote for medtech Start-ups!

Sleepiz logoSleepiz has produced innovative technology that will revolutionize the medical community. It is a patient-centered simple device that you can put on your bedside table. Their advanced equipment operates without cables and captures vital signs without touching the patient. With advanced statistical models and artificial intelligence, the device provides accurate analysis and insights to diagnose sleep disorders at home. 

 

As we mentioned before, for a Start-up to get onto this list is a big honour.The jury are all specialists in the start-up sector and chooses the 100 start-ups with the most significant potential in Switzerland. This is how it works; each expert chooses ten start-ups and ranks them from one to ten.  Subsequently, the start-ups with the highest scores are the ones that made it onto the list.

Top 100 Swiss Start-up Award brings the most innovative Swiss Start-ups into the public eye. This award is not only for Swiss Start-ups but also international companies. In the 10th anniversary edition, the first three positions went to Cutiss (1st), Wingtra (2nd), and Piavita (3rd). Additionally, the Public Voting award went to Acatena. At Hemex we wanted to contratulate these four start-ups, we believe they have a very promising and ground-breaking future. Therefore, we suggest you also keep an eye on them as well!

 

 About Hemex

Hemex is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

The next step in heart bypass technology

About 1,000,000 patients undergo highly invasive heart bypass surgery yearly. Our portfolio company AMT Medical has developed a unique technology to enable a safe, affordable, and minimally invasive coronary bypass surgery.

 

Every single day, millions of people suffer from Coronary Artery Disease (CAD). As the name suggests, it is a disease of coronary arteries, where usually these arteries get completely or partially blocked due to cholesterol deposits. CAD is the most common type of heart disease, and it is the leading cause of death in many countries of the world. This disease can have long and stable periods but might also become unstable at any time. CAD is a serious progressive and chronic disease that needs to be controlled and checked periodically.

In severe cases, Coronary Artery Bypass Graft (CABG) might be needed. CABG is a surgical procedure used to treat CAD. Coronary Artery Bypass Graft is performed when there is a blocked artery in the heart, or in emergency situations, such as heart attack if there is no response to other treatments. This procedure is highly invasive and is associated with long recovery times and serious complications, mainly due to the opening of the chest and stopping the beating of the heart during the surgery; these conditions could lead to complications during or after the surgery. 

AMT Medical is developing a unique coronary bypass system based on a technique used for similar indications in the brain. ELANA (Excimer Laser-Assisted Non-Occlusive Anastomosis), the sister company from AMT, introduced this procedure to the market for neurosurgery. Now AMT it’s applying it for CABG. ELANA enables a safe, affordable, and easy-to-use minimally invasive Coronary Artery Bypass Graft securing shorter recovery time and fewer complications. 

The AMT technique enables ELANA Coronary Bypass to be performed through small holes in the chest. Therefore the need to open the chest is not necessary anymore; neither is the heart-lung machine nor the suturing to hold the graft in place. For the patient, this means fewer chances of infections, internal bleeding, stroke, and much shorter recovery time. 

The European Commission awarded last year a consortium led by AMT Medical, including HEMEX, with a €2.2 M grant under its “Fast-Track to Innovation (FTI)” program. Under this proposal, HEMEX is in charge of planning, coordinating, and executing the multicentric, pan-European study in order to obtain the CE-mark for the Excimer Laser-Assisted Non-Occlusive Anastomosis (ELANA) Heart Bypass System in Patients undergoing Coronary Artery Bypass Grafts (CABG).

For more information on the progress of this life-changing therapy, please contact franziska.stemmler@hemex.ch

Co-funded by the Horizon 2020 Framework Programme of the European Union and the Grant Agreement (GA) No. 869922. 

About AMT Medical

AMT Medical is a pre-clinical stage medical device company from the Netherlands. Together with the UMC Utrecht is developing a unique coronary bypass system. AMT’s motivation is to develop simple ‘best in class’ coronary bypass technology through keyholes. The new standard, with lower costs for society, fewer complications, and a faster recovery for the patient.

 About Hemex

Hemex is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. We firmly believe in AMT Medical’s project, and we support them in diverse areas providing expertise. If you would like to know more about our work, you can find more information at HEMEX.

Swisscom StartUp Challenge – Pitch your 5G Case and Win!

This year, the program is aimed at start-ups and research teams whose solutions are based around the latest 5G mobile generation.

 

What is this year’s theme?

After seven successful editions, this year’s Swisscom StartUp Challenge has a unique theme for the first time and has taken on an international dimension. The program is aimed at start-ups or research teams whose solutions are based on the latest 5G mobile generation. It provides a unique chance for tech start-ups and research teams to pitch their products or functioning prototypes to an expert jury and win a weeklong Exploration Programme in Switzerland with a 5G innovator.

Who can participate?          

– Tech start-ups with a clear competitive edge that are ready to enter or have already entered the market.

– Research projects relating to 5G applications based, for example, at universities and other higher           education institutions. 

What can the ten finalists expect?

  • Participation in the pitch event on 17 December 2020 at the Swisscom Pirates Hub Zurich or via telepresence
  • Pitch training with personal feedback from venturelab experts to help prepare for the final on 3 December 2020
  • Analysis of business cooperation with Swisscom and investment by Swisscom Ventures
  • Easy access to the Swisscom and programme partner networks (Venturelab, Ericsson, Qualcomm)
  • Visibility thanks to inclusion in publicity surrounding the Swisscom StartUp Challenge

What can the five winners expect?

  • Working with the latest 5G architectures where E2E testing can take place
  • Access to the Swisscom 5G network at a range of locations 
  • Access to 5G smartphones, hotspots, tablets, laptops, existing Swisscom services, and testing tools
  • Support/mentoring by 5G experts from Swisscom and partner firms/program partners
  • Further development of marketing and sales skills
  • An unforgettable week in Switzerland including a visit to the Swiss Federal Institute of Technology and Swiss business/technology innovators

Where to apply?

Let’s shape the future together with the Swisscom StartUp Challenge! Apply with your 5G use case before 11 October HERE.

For general questions, contact Jennifer Adam (jennifer.adam@swisscom.com)

 

About the Swisscom StartUp Challenge

The Swisscom StartUp Challenge was launched in 2013. To date, they have been able to accompany numerous start-ups on their journey. They believe in the innovative strength of start-ups, and this year they are supporting 5G-related research projects. More at Swisscom.

 

About Hemex

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX.

Swiss Innovation Challenge – 2nd Round Pitches!

Outstanding swiss and international start-ups and SME’s presented yesterday their business projects at the 2nd round of the Swiss Innovation Challenge.  

 

The Swiss Innovation Challenge (SIC) is an innovation promotion program in which 25 finalists and one winner are selected from over 100 innovation projects in three elimination rounds. The participants in the competition are SMEs and start-ups from around the globe. SIC offers attractive awards and a unique 8-month acceleration program. Furthermore, it helps participants to build a concrete path towards recognition and business success. They benefit from individual coaching, tailored education, and extensive mentoring. This is a very important point for the participants, as they can get easier access to sponsors and potential business partners.

Over the last two days, the second pitch of SIC 2020 has taken place at the University of Applied Sciences and Arts Northwestern Switzerland. The 50 selected participants from the last round have presented their innovative projects in front of a very experienced jury. This second round has been very successful. Following safety guidelines to help prevent the spread of COVID-19, all participants and the jury wore face masks. The contestants presented (online and on-site) their projects with great enthusiasm to the jury.  

In this 6th edition, Hemex is supporting this Challenge with a special prize in the “Life Sciences” category. We were also very honored to be part of the jury for the first time. The participants’ devotion to their projects motivates us to continue working in the development of innovative solutions for the healthcare industry. Overall, 25 ventures will make it to the next stage and pitch in the 3rd round of this challenge. We would like to wish all start-ups the very best of luck! The award ceremony will take place in November.

 

About Hemex

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX.

Hemex Organizes Successful Biotech/Pharma Online Pitch Event

Hemex Online Pitching Event Label

Today, Juvabis, Inura Medical, SunRegen Healthcare, and Saverna Therapeutics have pitched their ventures at the HEMEX incubator to an online group of renowned international investors.

 

HEMEX frequently holds pitch events, where selected start-ups get the opportunity to pitch in front of potential investors. Since June, we have been organizing online Pitch Events to ensure safety for all participants. The focus of this morning’s pitch session was for start-ups seeking to revolutionize the fields of antimicrobial resistance, women’s health, neurodegeneration, and autoimmune diseases.

Today’s event kicked off with the start-up Juvabis AG. Sven Hobbie and Marc Creus, CEO and Head of BD at Juvabis respectively, presented their product pipeline which focuses on antimicrobial therapeutic drugs. They have developed a strategic opportunity to solve the problem of antimicrobial resistance (AMR).  Their program is an antibiotic-combination therapy for the treatment of drug-resistant infections in patients with limited treatment options. “We have an extremely robust base, concrete clinical data, and have a solid project which we are ready to push forward with”, Marc Creus tells Hemex after the presentation. “We were busy delivering, we have completed Phase I and now we are ready to start Phase II” added Sven Hobbie. Juvabis aims to develop innovative formulations that can be used to treat chronic, rare, and orphan diseases.

The second start-up pitching at our event was Inura Medical AG. Rafiq Hussain and Vanja Ivancevic, CEO and COO of Inura respectively, presented their innovative idea. Inura has developed an innovative patented urethral suppository for women, using an existing, approved drug with a well-known safety profile. It offers rescue therapy for a highly prevalent and disabling health disorder: overactive bladder syndrome (OAB). “In all my years working as a physician I have seen many women who are suffering from this disease, but the current treatment options do not work for everybody”, Rafiq Hussain tells Hemex, “patients would not hesitate to test another treatment, and we don’t want to give them another pill, so we are offering them a solution with a novel administration route that actually works” adds Vanja. This product facilitates the effective penetration of drugs through the urethral mucosal lining preventing the symptoms of this disease and reducing side effects. 

The third start-up pitching was Sunregen Healthcare AG. Mark Freedman, CEO of SunRegen, presented their innovative treatments for retinitis pigmentosa, a rare ophthalmological neurodegenerative disease. SunRegen has a potent, broad-acting, neuroprotective, neuro-rescuing small molecule that can be dosed orally and crosses the blood-brain barrier. Raw data proves that the compound plays a role in proteostasis and anti-apoptotic pathways, which provides additional rationale for its ability to protect and rescue a whole range of neurological stresses. “As a start-up, we need to find the right partner to help us go to the next stage” Mark explains to Hemex after his presentation, “and if we end up being right, this will make a huge impact and change the lives of people suffering from these neurodegenerative diseases.”

Last but not least, Saverna Therapeutics AG closed our Biotech/Pharma Pitch Event. Kamal Azzaoui, CEO of Saverna Therapeutics, presented their project which focuses on autoimmune diseases. Saverna uses integrated fragment-based screening (FBS) by Nuclear Magnetic Resonance (NMR) in-silico machine learning (ML), and cellular assays for drug discovery. The start-up has discovered a molecule that has shown cellular and in vivo activity, which would be a great candidate for Lupus disease. “We have the first molecule that is targeting the modulators of microRNA and we are proving that this platform works, which has huge potential to revolutionize drug discovery” explains Kamal to the Hemex team after his presentation.

Many thanks to Marc, Sven, Rafiq, Vanja, Mark, and Kamal for introducing us to their unique ideas in the fields of antimicrobial resistance, women’s health, neurodegeneration, and autoimmune diseases. We wish you good luck with your projects!

Are you interested in becoming an early-stage investor in one of these promising start-ups? Would you like to receive a personalized invitation to one of our next sessions?

Or are you interested in learning about how to create a great pitch deck that excites potential investors about your idea?

Then you are in the right place! Contact our start-up coach Franziska Stemmler for more information.

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub. Its primary focus is to bring innovative drugs, medical devices, and in–vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. Additionally, HEMEX helps and supports start-ups to find non-dilutive and dilutive funding. More at HEMEX